Seroatlas · Human Serome Atlas

SLC6A9

Sodium- and chloride-dependent glycine transporter 1

Also known as: GlyT-1, GLYT1, SC6A9_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P48067
Gene
SLC6A9
Ensembl
ENSG00000196517
Chromosome
1
Canonical length
706 aa
Protein class
Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters
Subcellular location
Nucleoplasm,Golgi apparatus

OverviewNCBI Gene

The amino acid glycine acts as an inhibitory neurotransmitter in the central nervous system. The protein encoded by this gene is one of two transporters that stop glycine signaling by removing it from the synaptic cleft. [provided by RefSeq, Jun 2016]

Canonical amino-acid sequenceUniProt

706 residues, UniProt reviewed canonical sequence.

>P48067|SLC6A9
     1  MSGGDTRAAI ARPRMAAAHG PVAPSSPEQV TLLPVQRSFF LPPFSGATPS TSLAESVLKV
    61  WHGAYNSGLL PQLMAQHSLA MAQNGAVPSE ATKRDQNLKR GNWGNQIEFV LTSVGYAVGL
   121  GNVWRFPYLC YRNGGGAFMF PYFIMLIFCG IPLFFMELSF GQFASQGCLG VWRISPMFKG
   181  VGYGMMVVST YIGIYYNVVI CIAFYYFFSS MTHVLPWAYC NNPWNTHDCA GVLDASNLTN
   241  GSRPAALPSN LSHLLNHSLQ RTSPSEEYWR LYVLKLSDDI GNFGEVRLPL LGCLGVSWLV
   301  VFLCLIRGVK SSGKVVYFTA TFPYVVLTIL FVRGVTLEGA FDGIMYYLTP QWDKILEAKV
   361  WGDAASQIFY SLGCAWGGLI TMASYNKFHN NCYRDSVIIS ITNCATSVYA GFVIFSILGF
   421  MANHLGVDVS RVADHGPGLA FVAYPEALTL LPISPLWSLL FFFMLILLGL GTQFCLLETL
   481  VTAIVDEVGN EWILQKKTYV TLGVAVAGFL LGIPLTSQAG IYWLLLMDNY AASFSLVVIS
   541  CIMCVAIMYI YGHRNYFQDI QMMLGFPPPL FFQICWRFVS PAIIFFILVF TVIQYQPITY
   601  NHYQYPGWAV AIGFLMALSS VLCIPLYAMF RLCRTDGDTL LQRLKNATKP SRDWGPALLE
   661  HRTGRYAPTI APSPEDGFEV QPLHPDKAQI PIVGSNGSSR LQDSRI

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLC6A9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
12
Mean surface accessibility (rSASA)
0.3
Highest tissue expression
77 nTPM

Expression across tissuesHPA

Tissue

  • spinal cord: 77 nTPM
  • skin: 43 nTPM
  • midbrain: 34 nTPM
  • adrenal gland: 29 nTPM
  • vagina: 23 nTPM
  • esophagus: 22 nTPM

Single-cell type

  • epicardial cells: 96 nCPM
  • adrenal cortex cells: 53 nCPM
  • retinal pigment epithelial cells: 51 nCPM
  • suprabasal keratinocytes: 36 nCPM
  • cone photoreceptor cells: 35 nCPM
  • retinal bipolar cells: 35 nCPM

Immune cell

  • naive CD4 T-cell: 0.1 nTPM
  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM

Brain region

  • white matter: 148 nTPM
  • medulla oblongata: 139 nTPM
  • cerebellum: 111 nTPM
  • pons: 100 nTPM
  • spinal cord: 96 nTPM
  • thalamus: 95 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLC6A9.

Disease | AllUniProt

Conditions SLC6A9 is implicated in, by any mechanism.

  • Glycine encephalopathy with normal serum glycine (GCENSG) MIM:617301

Disease | GeneticClinVar

14 pathogenic / likely-pathogenic of 382 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Atypical glycine encephalopathy

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.63
gnomAD pLI
0
gnomAD missense Z
1.98
DepMap mean gene effect
-0.24
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of SLC6A9 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLC6A9 as an antibody target. Whether an autoantibody or antibody against SLC6A9 could matter depends on whether native SLC6A9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLC6A9 is annotated at the cell surface, where native SLC6A9 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLC6A9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/SLC6A9. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...